Association Of FTO Variant Rs9939609 With Type 2 Diabetes Mellitus And Obesity In A Chinese Han Population

Objective This study aimed to examine the relationships between FTO variant rs9939609 and type 2 diabetes mellitus (T2DM) as well as obesity in a Chinese Han population. Methods FTO variant rs9939609 was genotyped in 627 individuals consisting of 322 T2DM cases and 305 normal glucose tolerant controls (NC) using TaqMan genotyping allelic discrimination assay. Anthropometric, biochemical variables were examined in total subjects. Results 1. The frequency of the A allele carriers was significantly higher in the T2DM group than in the control group (16.8% vs.12.6%, P=0.038).The distribution of AA and AT genotype was higher in T2DM subjects than in NC controls (P=0.027). The frequency of the A allele carriers in obese was significantly higher than that in the non-obese individuals (18.0% vs.12.8%, P=0.012).2. Compared with TT subjects, AA and AT carriers of rs9939609 had a higher risk of T2DM (OR=1.489[1.017-2.180], P=0.041), but the association was disappeared after adjustment for BMI. The FTO rs9939609 A allele was associated with an increased risk of obesity (OR=1.641 [1.141-2.359], P=0.008).3. In T2DM subjects, the allele A carriers of rs9939609 had higher BMI and diastolic blood pressure (P<0.05), but the correlation with blood pressure was disappeared after adjustment for BMI. In T2DM group, the A allele carriers was also associated with an increased risk of obesity (OR=1.752 [1.065-2.882], P=0.027). Conclusions FTO rs9939609 is associated with T2DM and obesity in a Chinese Han population, and this correlation might be mediated through BMI. Carriers of A allele in T2DM cases had higher BMI and diastolic blood pressure. The correlation between diastolic blood pressure of type 2 diabetes mellitus and rs9939609 SNP might be mediated through BMI. Objective To investigate the plasma concentration of visfatin in type 2 diabetes patients and normal controls and its correlation with the metabolic characteristics of type 2 diabetes mellitus. Methods Fasting plasma visfatin was determined in 205 T2D subjects and 171 normal glucose tolerant controls.Anthropometric, biochemical variables were examined in total subjects. Visfatin was measured with EIA assay. Results 1. T2DM cases had significant higher visfatin level than controls (3.45+ 1.24 vs.2.76±0.88,P<0.001), the difference persisted after adjustment for age, sex, BMI. Plasma visfatin in obese was not significantly increased than that in the non-obese individuals (P>0.05).2. In T2DM cases, fasting plasma visfatin was found to correlation positively and significantly with diastolic blood pressure,30 minute plasma glucose, but negatively with HOMA-B and urinary albumin. Multiple regression analysis showed diastolic blood pressure and HOMA-B were independent related factors influencing plasma visfatin level. Conclusions Visfatin is elevated in T2DM patients independent of age, sex and adiposity. Obesity may not lead to visfatin increase absolutely and significantly. In T2DM patients, diastolic blood pressure and pancreatic-B cell function were main factors influencing plasma visfatin level.